Purpose of the study
====================

Selection of initial antiretroviral therapy (ART) may be informed by factors such as efficacy, adverse effects, and cost. This study assessed the lifetime cost-effectiveness of atazanavir-ritonavir (ATV/r) versus lopinavir-ritonavir (LPV/r) in HIV patients initiating first-line ART.

Methods
=======

A Markov microsimulation model was developed to project lifetime health-related outcomes, costs, quality-adjusted life years (QALYs), and cost-effectiveness of ATV/r versus LPV/r, both with tenofovir-emtricitabine, as first-line ART. Virologic suppression, baseline characteristics, state transition probabilities, cholesterol changes, and adverse effects were based on 96-week CASTLE results. HIV-related mortality, opportunistic infection (OI) and AIDS rates, coronary heart disease (CHD) risk, treatment adherence, costs, and utilities were obtained from published sources. Costs were reported in 2009 US dollars. Sensitivity analyses were conducted to assess the robustness of study results.

Summary of results
==================

Compared with patients initiating LPV/r, patients initiating ATV/r were estimated to have longer time in first-line therapy, fewer cases of AIDS, OI, CHD, and diarrhea, more cases of hyperbilirubinemia (HB), and higher costs. While absolute survival was similar, patients initiating ATV/r were predicted to have longer quality-adjusted survival. Overall, ATV/r added 0.26 QALYs at a cost of \$6,826, producing an ICER of \$26,421 per QALY gained. Sensitivity analyses indicated that at a willingness to pay threshold of \$50,000 per QALY, ATV/r was cost effective 94% of the time. Table [1](#T1){ref-type="table"}

  Health-Related Outcomes                                                                                                                                                                                                                                                   
  ------------------------------------ --------------------------------------- ------------------------------------- ----------------------------------- ------------------------------------ ----------------------------------------- ----------------------------------- --------------------------------
                                       Time on First-Line Treatment (months)   AIDS cases (per 1000 patient years)   OI cases (per 1000 patient years)   CHD cases (per 1000 patient years)   Diarrhea cases (per 1000 patient years)   HB cases (per 1000 patient years)   Absolute Survival (life years)
                                                                                                                                                                                                                                                                            
  LPV/r                                70.7                                    20.054                                0.519                               5.511                                6.262                                     0.247                               18.51
                                                                                                                                                                                                                                                                            
  ATV/r                                97.3                                    19.081                                0.443                               5.437                                1.272                                     6.986                               18.52
                                                                                                                                                                                                                                                                            
  Cost, QALY, and Cost-Effectiveness                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                            
                                       Cost                                    Incremental Cost                      Quality-Adjusted Survival (QALY)    Incremental QALY                     Incremental Cost-Effectiveness                                                
                                                                                                                                                                                                                                                                            
  LPV/r                                \$269,160                               \--                                   10.761                              \--                                  \--                                                                           
                                                                                                                                                                                                                                                                            
  ATV/r                                \$275,986                               \$6,826                               11.020                              0.258                                \$26,421                                                                      

Conclusions
===========

Accounting for both lifetime costs and QALYs, ATV/r is cost effective (less than \$50,000 per QALY) compared with LPV/r in HIV patients initiating first-line ART.
